On September 29, 2023, the FDA proposed a rule to tighten control over Laboratory Developed Tests (LDTs), supplanting the CMS as regulators. While supporters emphasize the need for safety, critics, especially in the medical community, fear the rule could stifle innovation, jeopardizing independent laboratories and escalating healthcare costs.